P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

• Afshin Mashadi-Hossein,
• Julie Rytlewski,
• MD Shamsuzzaman,
• Debashree Basudhar,
• Mandeep Takhar,
• Ana Kostic,
• Timothy B. Campbell,
• Salomon Manier,
• Yi Lin,
• Nathan Martin

Affiliations

Afshin Mashadi-Hossein

1 Bristol Myers Squibb, Princeton, United States

Julie Rytlewski

1 Bristol Myers Squibb, Princeton, United States

MD Shamsuzzaman

1 Bristol Myers Squibb, Princeton, United States

Debashree Basudhar

1 Bristol Myers Squibb, Princeton, United States

Mandeep Takhar

1 Bristol Myers Squibb, Princeton, United States

Ana Kostic

1 Bristol Myers Squibb, Princeton, United States

Timothy B. Campbell

1 Bristol Myers Squibb, Princeton, United States

Salomon Manier

2 Lille University Hospital, Lille, France

Yi Lin

3 Mayo Clinic, Rochester, United States

Nathan Martin

1 Bristol Myers Squibb, Princeton, United States